Hometop nav spacerAbout ARStop nav spacerHelptop nav spacerContact Ustop nav spacerEn Espanoltop nav spacer
Bookmark This PageShare/Bookmark   Printable VersionPrintable Version     E-mail this pageE-mail this page
United States Department of Agriculture Agricultural Research Service
Search
 
 
Search News & Events
News
News archive
News by e-mail
Nutrition news
Magazine 
Image Gallery
Noticias en español
Press Room
Video
Briefing Room
Events
   

 

Shipping Fever Vaccine Nears Market

By Linda McGraw
December 21, 1998

Cows headed to feedlots may soon be getting a protective vaccine against shipping fever, a disease that costs U.S. and Canadian producers more than $1 billion annually.

Scientists developed the genetically engineered vaccine at the Agricultural Research Service, the chief scientific arm of the U.S. Department of Agriculture.

The disease is the biggest killer of beef cattle in feedlots, according to veterinarian Robert E. Briggs at ARS' National Animal Disease Center in Ames, Iowa.

Three different bacteria can cause shipping fever, which ultimately results in pneumonia. The disease strikes cattle about a week after they’re transported from the cow and calf operations where they were born to the feedlots where they finish their growth. When the animals arrive at the feedlot, they may show a variety of disease symptoms, including decreased appetite, fever, coughing and nasal discharge.

Briggs and ARS microbiologist Fred M. Tatum developed the world’s first genetically engineered vaccine strains for this costly disease. They didn’t use foreign DNA or a marker for antibiotic resistance to make the vaccine. Rather, they created the live vaccine by deleting a large piece of a gene called aroA from each of the three culprit bacteria. Without this gene, the bacteria cannot cause infection.

Several patents have been issued jointly to ARS and the Biotechnology Research and Development Consortium in Peoria, Ill. The consortium is a public-private business formed to speed commercialization of government-funded research discoveries. Schering-Plough of Madison, N.J., is a member company that has licensed the technology to make multivalent injectable vaccines. The firm is currently seeking approval to market the product.

An article about the research appears in the December issue of Agricultural Research magazine. The story is also on the World Wide Web at:

http://www.ars.usda.gov/is/AR/archive/dec98/fever1298.htm

Scientific contact: Robert E. Briggs and Fred M. Tatum, ARS National Animal Disease Center, Ames, Iowa, phone (515) 239-8639, fax (515) 239-8458, bbriggs@nadc.ars.usda.gov and tatum@nadc.ars.usda.gov

[Top]
     
Last Modified: 01/03/2002
ARS Home | USDA.gov | Site Map | Policies and Links 
FOIA | Accessibility Statement | Privacy Policy | Nondiscrimination Statement | Information Quality | USA.gov | White House